| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A S Khachaturian, J J Gallo, J C Breitne. Performance characteristics of a two-stage dementia screen in a population sample. Journal of clinical epidemiology. vol 53. issue 5. 2000-06-14. PMID:10812327. |
after adjustment for age, the efficiency of the both 3ms/iqcode and the dq was better for subjects with genotype epsilon4/epsilon4 at apoe, better among women, and better in those with two or more years duration of dementia. |
2000-06-14 |
2023-08-12 |
human |
| C Dufouil, C Tzourio, C Brayne, C Berr, P Amouyel, A Alpérovitc. Influence of apolipoprotein E genotype on the risk of cognitive deterioration in moderate drinkers and smokers. Epidemiology (Cambridge, Mass.). vol 11. issue 3. 2000-06-08. PMID:10784244. |
the apoe epsilon4 allele is an established risk factor for dementia and cognitive impairment. |
2000-06-08 |
2023-08-12 |
human |
| I Alafuzoff, S Helisalmi, A Mannermaa, H Soinine. Severity of cardiovascular disease, apolipoprotein E genotype, and brain pathology in aging and dementia. Annals of the New York Academy of Sciences. vol 903. 2000-06-02. PMID:10818513. |
on the other hand, the extent of vascular lesions currently used for the diagnosis of vascular dementia (vad) showed correlation with the cardiovascular index, whereas apoe epsilon 4 allele did not seem to influence the extent of vascular lesions. |
2000-06-02 |
2023-08-12 |
Not clear |
| F van Leuve. Single and multiple transgenic mice as models for Alzheimer's disease. Progress in neurobiology. vol 61. issue 3. 2000-05-31. PMID:10727777. |
mice overexpressing human presenilin 1, apoe 4 and protein tau to generate "multiple" transgenic mice, offer additional potential to define the pathological interactions of these genetic factors, known to be involved, directly or indirectly, in dementia of the alzheimer type. |
2000-05-31 |
2023-08-12 |
mouse |
| M Bonarek, P Barberger-Gateau, L Letenneur, V Deschamps, A Iron, B Dubroca, J F Dartigue. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology. vol 19. issue 3. 2000-05-04. PMID:10705232. |
elevated high-density lipoprotein cholesterol was associated with a significantly decreased risk of dementia, independent of apoe status and other potential confounding variables, suggesting that cholesterol fractions could be involved in both alzheimer's disease and vascular dementia. |
2000-05-04 |
2023-08-12 |
human |
| V N Trieu, F M Ucku. Apolipoprotein E and apolipoprotein D expression in a murine model of singlet oxygen-induced cerebral stroke. Biochemical and biophysical research communications. vol 268. issue 3. 2000-03-22. PMID:10679292. |
the insights gained from this study should facilitate the elucidation of the role of apoe in neurological disorders such as dementia with stroke and alzheimer's disease. |
2000-03-22 |
2023-08-12 |
mouse |
| X A Alvarez, R Mouzo, V Pichel, P Pérez, M Laredo, L Fernández-Novoa, L Corzo, R Zas, M Alcaraz, J J Secades, R Lozano, R Cacabelo. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods and findings in experimental and clinical pharmacology. vol 21. issue 9. 2000-02-28. PMID:10669911. |
as compared to placebo, citicoline improved cognitive performance in alzheimer's disease patients with apoe e4 (adas: difference between groups = -3.2 +/- 1.8 scores, p < 0.05; adas-cog: difference between groups = -2.3 +/- 1.5, ns); and this improvement on cognition was more pronounced (adas, p < 0.01; adas-cog: difference between groups = -2.8 +/- 1.3, p < 0.06) in patients with mild dementia (gds < 5). |
2000-02-28 |
2023-08-12 |
Not clear |
| M Prince, S Lovestone, J Cervilla, S Joels, J Powell, C Russ, A Man. The association between APOE and dementia does not seem to be mediated by vascular factors. Neurology. vol 54. issue 2. 2000-02-18. PMID:10668701. |
the association between apoe and dementia does not seem to be mediated by vascular factors. |
2000-02-18 |
2023-08-12 |
Not clear |
| M Prince, S Lovestone, J Cervilla, S Joels, J Powell, C Russ, A Man. The association between APOE and dementia does not seem to be mediated by vascular factors. Neurology. vol 54. issue 2. 2000-02-18. PMID:10668701. |
the effect of apoe on dementia may be mediated through dyslipidemia and atherogenesis through its effect on cholesterol metabolism. |
2000-02-18 |
2023-08-12 |
Not clear |
| K Juva, A Verkkoniemi, P Viramo, T Polvikoski, K Kainulainen, K Kontula, R Sulkav. APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology. vol 54. issue 2. 2000-02-18. PMID:10668704. |
apoe epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. |
2000-02-18 |
2023-08-12 |
Not clear |
| L Zhu, L Fratiglioni, Z Guo, H Basun, E H Corder, B Winblad, M Viitane. Incidence of dementia in relation to stroke and the apolipoprotein E epsilon4 allele in the very old. Findings from a population-based longitudinal study. Stroke. vol 31. issue 1. 2000-02-07. PMID:10625715. |
both stroke and the apolipoprotein e (apoe) epsilon4 allele increase the risk of dementia. |
2000-02-07 |
2023-08-12 |
Not clear |
| L Zhu, L Fratiglioni, Z Guo, H Basun, E H Corder, B Winblad, M Viitane. Incidence of dementia in relation to stroke and the apolipoprotein E epsilon4 allele in the very old. Findings from a population-based longitudinal study. Stroke. vol 31. issue 1. 2000-02-07. PMID:10625715. |
however, the interaction between stroke and apoe on dementia is still unclear. |
2000-02-07 |
2023-08-12 |
Not clear |
| J Thome, J C Gewirtz, N Sakai, V Zachariou, P Retz-Junginger, W Retz, R S Duman, M Rösle. Polymorphisms of the human apolipoprotein E promoter and bleomycin hydrolase gene: risk factors for Alzheimer's dementia? Neuroscience letters. vol 274. issue 1. 2000-02-04. PMID:10530514. |
in addition to the apolipoprotein e (apoe) tri-allele polymorphism, genetic variants of the apolipoprotein e promoter (-491a/t) and the bleomycin hydrolase (bh-pen) gene have also been proposed as genetic risk factors for alzheimer's dementia (ad). |
2000-02-04 |
2023-08-12 |
human |
| P de Knijff, C M van Duij. Role of APOE in dementia: A critical reappraisal. Haemostasis. vol 28. issue 3-4. 1999-12-22. PMID:10420066. |
role of apoe in dementia: a critical reappraisal. |
1999-12-22 |
2023-08-12 |
Not clear |
| J M Johnston, J A Cauley, M Gangul. APOE 4 and hip fracture risk in a community-based study of older adults. Journal of the American Geriatrics Society. vol 47. issue 11. 1999-12-07. PMID:10573444. |
to investigate whether the apoe 4 allele was associated with increased risk of hip fracture in an older community-based sample and whether such an increased risk was independent of dementia and history of falling. |
1999-12-07 |
2023-08-12 |
Not clear |
| M Kanai, M Shizuka, K Urakami, E Matsubara, Y Harigaya, K Okamoto, M Shoj. Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neuroscience letters. vol 267. issue 1. 1999-12-06. PMID:10400250. |
the apoe epsilon4 allele accelerates the progression of dementia and increases the levels of csf tau in ad patients. |
1999-12-06 |
2023-08-12 |
Not clear |
| A J Slooter, M Cruts, A Ott, M L Bots, J C Witteman, A Hofman, C Van Broeckhoven, M M Breteler, C M van Duij. The effect of APOE on dementia is not through atherosclerosis: the Rotterdam Study. Neurology. vol 53. issue 7. 1999-11-03. PMID:10534277. |
the effect of apoe on dementia is not through atherosclerosis: the rotterdam study. |
1999-11-03 |
2023-08-12 |
Not clear |
| A J Slooter, M Cruts, A Ott, M L Bots, J C Witteman, A Hofman, C Van Broeckhoven, M M Breteler, C M van Duij. The effect of APOE on dementia is not through atherosclerosis: the Rotterdam Study. Neurology. vol 53. issue 7. 1999-11-03. PMID:10534277. |
we studied, in a population-based setting (244 dementia cases; 1,002 nondemented controls), whether apoe is associated with dementia through atherosclerosis. |
1999-11-03 |
2023-08-12 |
Not clear |
| L M McConnell, G D Sanders, D K Owen. Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. Genetic testing. vol 3. issue 1. 1999-10-21. PMID:10464577. |
however, although the medical community holds the near-unanimous opinion that apoe genotyping should not be used for prediction in asymptomatic individuals, controversy remains about whether it should be used for diagnosis in patients who show signs of dementia. |
1999-10-21 |
2023-08-12 |
Not clear |
| L F Lue, Y M Kuo, A E Roher, L Brachova, Y Shen, L Sue, T Beach, J H Kurth, R E Rydel, J Roger. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. The American journal of pathology. vol 155. issue 3. 1999-10-07. PMID:10487842. |
we have characterized amyloid beta peptide (abeta) concentration, abeta deposition, paired helical filament formation, cerebrovascular amyloid angiopathy, apolipoprotein e (apoe) allotype, and synaptophysin concentration in entorhinal cortex and superior frontal gyrus of normal elderly control (nd) patients, alzheimer's disease (ad) patients, and high pathology control (hpc) patients who meet pathological criteria for ad but show no synapse loss or overt antemortem symptoms of dementia. |
1999-10-07 |
2023-08-12 |
Not clear |